Literature DB >> 27606094

Idiopathic pulmonary fibrosis: past, present, future-a review from Talmadge King's ATS 2016 presentation.

S Clark Berngard1, Kamyar Afshar1.   

Abstract

Entities:  

Year:  2016        PMID： 27606094      PMCID： PMC4990691          DOI： 10.21037/jtd.2016.07.31

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  18 in total

1.  Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis.

Authors: 
Journal:  N Engl J Med       Date:  2015-08-20       Impact factor: 91.245

2.  International guidelines for the selection of lung transplant candidates: 2006 update--a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation.

Authors:  Jonathan B Orens; Marc Estenne; Selim Arcasoy; John V Conte; Paul Corris; Jim J Egan; Thomas Egan; Shaf Keshavjee; Christiane Knoop; Robert Kotloff; Fernando J Martinez; Steven Nathan; Scott Palmer; Alec Patterson; Lianne Singer; Gregory Snell; Sean Studer; J L Vachiery; Allan R Glanville
Journal:  J Heart Lung Transplant       Date:  2006-07       Impact factor: 10.247

3.  Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial.

Authors:  Jürgen Behr; Elisabeth Bendstrup; Bruno Crestani; Andreas Günther; Horst Olschewski; C Magnus Sköld; Athol Wells; Wim Wuyts; Dirk Koschel; Michael Kreuter; Benoît Wallaert; Chin-Yu Lin; Jürgen Beck; Carlo Albera
Journal:  Lancet Respir Med       Date:  2016-05-05       Impact factor: 30.700

4.  Radiologic-pathologic discordance in biopsy-proven usual interstitial pneumonia.

Authors:  Kunihiro Yagihashi; Jason Huckleberry; Thomas V Colby; Henry D Tazelaar; Jordan Zach; Baskaran Sundaram; Sudhakar Pipavath; Marvin I Schwarz; David A Lynch
Journal:  Eur Respir J       Date:  2016-02-25       Impact factor: 16.671

5.  Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.

Authors:  Ganesh Raghu; Kevin J Anstrom; Talmadge E King; Joseph A Lasky; Fernando J Martinez
Journal:  N Engl J Med       Date:  2012-05-20       Impact factor: 91.245

Review 6.  Idiopathic pulmonary fibrosis.

Authors:  Talmadge E King; Annie Pardo; Moisés Selman
Journal:  Lancet       Date:  2011-06-28       Impact factor: 79.321

7.  Prevalence and prognosis of unclassifiable interstitial lung disease.

Authors:  Christopher J Ryerson; Thomas H Urbania; Luca Richeldi; Joshua J Mooney; Joyce S Lee; Kirk D Jones; Brett M Elicker; Laura L Koth; Talmadge E King; Paul J Wolters; Harold R Collard
Journal:  Eur Respir J       Date:  2012-12-06       Impact factor: 16.671

8.  A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.

Authors:  Talmadge E King; Williamson Z Bradford; Socorro Castro-Bernardini; Elizabeth A Fagan; Ian Glaspole; Marilyn K Glassberg; Eduard Gorina; Peter M Hopkins; David Kardatzke; Lisa Lancaster; David J Lederer; Steven D Nathan; Carlos A Pereira; Steven A Sahn; Robert Sussman; Jeffrey J Swigris; Paul W Noble
Journal:  N Engl J Med       Date:  2014-05-18       Impact factor: 91.245

9.  Interobserver agreement for the ATS/ERS/JRS/ALAT criteria for a UIP pattern on CT.

Authors:  Simon L F Walsh; Lucio Calandriello; Nicola Sverzellati; Athol U Wells; David M Hansell
Journal:  Thorax       Date:  2015-11-19       Impact factor: 9.139

10.  Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.

Authors:  Steven D Nathan; Carlo Albera; Williamson Z Bradford; Ulrich Costabel; Roland M du Bois; Elizabeth A Fagan; Robert S Fishman; Ian Glaspole; Marilyn K Glassberg; Kenneth F Glasscock; Talmadge E King; Lisa Lancaster; David J Lederer; Zhengning Lin; Carlos A Pereira; Jeffrey J Swigris; Dominique Valeyre; Paul W Noble; Athol U Wells
Journal:  Thorax       Date:  2016-03-11       Impact factor: 9.139
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.